Rachel A Murphy1, Steven Moore2, Mary Playdon2, Stephen Kritchevsky3, Anne B Newman4, Suzanne Satterfield5, Hilsa Ayonayon6, Clary Clish7, Robert Gerszten7, Tamara B Harris8. 1. Centre of Excellence in Cancer Prevention, School of Population and Public Health, University of British Columbia, Vancouver, Canada. 2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland. 3. Stitch Center on Aging, Wake Forest School of Medicine, Winston-Salem, North Carolina. 4. Center for Aging and Population Health, Department of Epidemiology, University of Pittsburgh, Pennsylvania. 5. Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis. 6. Department of Epidemiology and Biostatistics, University of California, San Francisco. 7. Broad Institute of MIT and Harvard, Cambridge, Massachusetts. 8. Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Bethesda, Maryland.
Abstract
Background: Metabolic pathways that give rise to functional decline and mobility disability in older adults are incompletely understood. Methods: To identify metabolic perturbations that may affect functional decline, nontargeted metabolomics was used to measure 350 metabolites in baseline plasma from 313 black men in the Health ABC Study (median age 74 years). Usual gait speed was measured over 20 m. Cross-sectional relationships between gait speed and metabolites were explored with partial correlations adjusted for age, study site, and smoking status. Risk of incident mobility disability (two consecutive reports of severe difficulty walking quarter mile or climb 10 stairs) over 13 years of follow-up was explored with Cox regression models among 307 men who were initially free of mobility disability. Significance was determined at p ≤ .01 and q (false discovery rate) ≤ 0.30. Results: Two metabolites were correlated with gait speed: salicylurate (r = -.19) and 2-hydroxyglutarate (r = -.18). Metabolites of amino acids and amino acid degradation (indoxy sulfate; hazard ratio [HR] = 1.48, 95% confidence interval [CI] = 1.09-2.03, symmetric dimethylarginine; HR = 3.58, 95% CI = 1.57-8.15, N-carbamoyl beta-alanine; HR = 1.91, 95% CI = 1.16-3.14, quinolinate; HR = 2.56, 95% CI = 1.65-3.96) and metabolites related to kidney function (aforementioned symmetric dimethylarginine and indoxy sulfate as well as creatinine; HR = 5.91, 95% CI = 2.06-16.9, inositol; HR = 2.70, 95% CI = 1.47-4.97) were among the 23 metabolites associated with incident mobility disability. Conclusions: This study highlights the potential role of amino acid derivatives and products and kidney function early in the development of mobility disability and suggests metabolic profiles could help identify individuals at risk of functional decline.
Background: Metabolic pathways that give rise to functional decline and mobility disability in older adults are incompletely understood. Methods: To identify metabolic perturbations that may affect functional decline, nontargeted metabolomics was used to measure 350 metabolites in baseline plasma from 313 black men in the Health ABC Study (median age 74 years). Usual gait speed was measured over 20 m. Cross-sectional relationships between gait speed and metabolites were explored with partial correlations adjusted for age, study site, and smoking status. Risk of incident mobility disability (two consecutive reports of severe difficulty walking quarter mile or climb 10 stairs) over 13 years of follow-up was explored with Cox regression models among 307 men who were initially free of mobility disability. Significance was determined at p ≤ .01 and q (false discovery rate) ≤ 0.30. Results: Two metabolites were correlated with gait speed: salicylurate (r = -.19) and 2-hydroxyglutarate (r = -.18). Metabolites of amino acids and amino acid degradation (indoxy sulfate; hazard ratio [HR] = 1.48, 95% confidence interval [CI] = 1.09-2.03, symmetric dimethylarginine; HR = 3.58, 95% CI = 1.57-8.15, N-carbamoyl beta-alanine; HR = 1.91, 95% CI = 1.16-3.14, quinolinate; HR = 2.56, 95% CI = 1.65-3.96) and metabolites related to kidney function (aforementioned symmetric dimethylarginine and indoxy sulfate as well as creatinine; HR = 5.91, 95% CI = 2.06-16.9, inositol; HR = 2.70, 95% CI = 1.47-4.97) were among the 23 metabolites associated with incident mobility disability. Conclusions: This study highlights the potential role of amino acid derivatives and products and kidney function early in the development of mobility disability and suggests metabolic profiles could help identify individuals at risk of functional decline.
Authors: J M Guralnik; L Ferrucci; C F Pieper; S G Leveille; K S Markides; G V Ostir; S Studenski; L F Berkman; R B Wallace Journal: J Gerontol A Biol Sci Med Sci Date: 2000-04 Impact factor: 6.053
Authors: Helen Lum; Richard Sloane; Kim M Huffman; Virginia B Kraus; Dana K Thompson; William E Kraus; James R Bain; Robert Stevens; Carl F Pieper; Gregory A Taylor; Christopher B Newgard; Harvey J Cohen; Miriam C Morey Journal: J Gerontol A Biol Sci Med Sci Date: 2011-03-02 Impact factor: 6.053
Authors: Rachel A Murphy; Steven C Moore; Mary Playdon; Osorio Meirelles; Anne B Newman; Iva Milijkovic; Stephen B Kritchevsky; Ann Schwartz; Bret H Goodpaster; Joshua Sampson; Peggy Cawthon; Eleanor M Simonsick; Robert E Gerszten; Clary B Clish; Tamara B Harris Journal: J Gerontol A Biol Sci Med Sci Date: 2017-10-01 Impact factor: 6.053
Authors: Eugene P Rhee; Clary B Clish; Anahita Ghorbani; Martin G Larson; Sammy Elmariah; Elizabeth McCabe; Qiong Yang; Susan Cheng; Kerry Pierce; Amy Deik; Amanda L Souza; Laurie Farrell; Carly Domos; Robert W Yeh; Igor Palacios; Kenneth Rosenfield; Ramachandran S Vasan; Jose C Florez; Thomas J Wang; Caroline S Fox; Robert E Gerszten Journal: J Am Soc Nephrol Date: 2013-05-16 Impact factor: 10.121
Authors: M P Heyes; K Saito; J S Crowley; L E Davis; M A Demitrack; M Der; L A Dilling; J Elia; M J Kruesi; A Lackner Journal: Brain Date: 1992-10 Impact factor: 13.501
Authors: Alison M Mondul; Steven C Moore; Stephanie J Weinstein; Edward D Karoly; Joshua N Sampson; Demetrius Albanes Journal: Int J Cancer Date: 2015-05-09 Impact factor: 7.396
Authors: Marta Gonzalez-Freire; Ruin Moaddel; Kai Sun; Elisa Fabbri; Pingbo Zhang; Mohammed Khadeer; Norman Salem; Luigi Ferrucci; Richard D Semba Journal: J Gerontol A Biol Sci Med Sci Date: 2019-01-01 Impact factor: 6.053
Authors: Megan M Marron; Stacy G Wendell; Robert M Boudreau; Clary B Clish; Adam J Santanasto; George C Tseng; Joseph M Zmuda; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2020-11-13 Impact factor: 6.053
Authors: Qianqian Gu; John J Spinelli; Trevor B J Dummer; Treena E McDonald; Steven C Moore; Rachel A Murphy Journal: Sci Rep Date: 2018-11-02 Impact factor: 4.379
Authors: Luke Whiley; Leanne C Nye; Isobelle Grant; Nick Andreas; Katie E Chappell; Magali H Sarafian; Ravi Misra; Robert S Plumb; Matthew R Lewis; Jeremy K Nicholson; Elaine Holmes; Jonathan R Swann; Ian D Wilson Journal: Anal Chem Date: 2019-03-25 Impact factor: 6.986
Authors: Li Meng; Hong Shi; Da-Guang Wang; Jing Shi; Wen-Bin Wu; Ya-Min Dang; Guo-Qing Fan; Ji Shen; Pu-Lin Yu; Jun Dong; Rui-Yue Yang; Huan Xi Journal: Front Med (Lausanne) Date: 2022-01-28
Authors: Jovia L Nierenberg; Jiang He; Changwei Li; Xiaoying Gu; Mengyao Shi; Alexander C Razavi; Xuenan Mi; Shengxu Li; Lydia A Bazzano; Amanda H Anderson; Hua He; Wei Chen; Jack M Guralnik; Jason M Kinchen; Tanika N Kelly Journal: Aging (Albany NY) Date: 2020-06-01 Impact factor: 5.682
Authors: Megan M Marron; Tamara B Harris; Robert M Boudreau; Clary B Clish; Steven C Moore; Rachel A Murphy; Venkatesh L Murthy; Jason L Sanders; Ravi V Shah; George C Tseng; Stacy G Wendell; Joseph M Zmuda; Anne B Newman Journal: Metabolites Date: 2019-04-30